InvestmentAug 13, 2026, 09:11 AM
MapLight Therapeutics Secures $150M PIPE Financing
AI Summary
MapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds. The financing involves the sale of common stock and pre-funded warrants to institutional and accredited investors. The company plans to use the proceeds primarily to advance its ML-007C-MA program, including ongoing Phase 2 and registrational Phase 3 studies, and for general corporate purposes. This financing, combined with existing cash of $351.3 million as of June 30, 2026, is expected to fund operations through 2028.
Key Highlights
- Secured $150 million in gross proceeds from a private placement financing (PIPE).
- Sold 9,197,887 shares of common stock at $11.38 per share.
- Sold pre-funded warrants for 3,983,168 shares at $11.3799 per warrant.
- Proceeds will fund ML-007C-MA development, including VISTA Phase 2 and ZEPHYR-2 Phase 3 studies.
- Cash, cash equivalents, and investments totaled $351.3 million as of June 30, 2026.
- Financing is expected to extend cash runway through 2028.
Price Impact
More from MPLT